KALA BIO posts Q4 net loss of $8.2M; Phase 2b topline data delayed to 3Q25

KALA BIO, Inc.

2025-Q1 EPS reported -$1.41 vs consensus -$103.53 ▲ beat (+98.6%)

Randomized 87 patients in Phase 2b CHASE trial for KPI-012; extending enrollment due to 13 unverified patients; topline data now expected in 3Q25.
Raised $10.75M in December private placement with SR One, Cormorant, Woodline.
Cash and equivalents $51.2M at year-end; expected to fund operations into 1Q26.
Q4 operating loss $9.5M; net loss $8.2M ($1.74/share).
Full year 2024 net loss $38.5M ($10.15/share); no revenue.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.